The American Diabetes Association will present their 74th Scientific Sessions event on June 13-17, 2014. It will be held at the Moscone Center in San Francisco, California. Sign up
for our daily e-mail blasts on our registration page, and check back here during the conference for full coverage.
Can Early Use of Insulin, GLP-1 Halt Diabetes Progression?
For years, the standard for treating type 2 diabetes mellitus (T2DM) has been step therapy. Patients are told to make changes in their diets and to exercise more. Then, most start metformin; if T2DM progresses, doctors add drugs from among the dozen other classes, either alone but typically in combination.
Behavioral Health Session Tackles Diabetic “Burnout,” Mental Health Delivery
A symposium that focused on the relationship between behavioral health and diabetes examined how the challenges of living with the disease wear on patients over time, ahead of results presented Sunday showing that much of what is diagnosed as "depression" in diabetes may not be. Presenters offered 3 models for better coordination of care.
Diabetes Navigator Program Reduces A1C Levels for Patients in Alabama
A diabetes patient navigator program in Birmingham, Alabama, a joint project of the American Academy of Family Physicians Foundation and Sanofi US, resulted in lower A1C levels for its participants. Patients also reported higher levels of satisfaction in managing their disease.
Studies on Fat in Youth Show That Risks Emerge Early, and Are Hard to Reverse
Studies presented at the American Diabetes Association's meeting in San Francisco took a deeper look at what the presence of fat does to overweight children. Researchers found that signs of trouble emerge early, with implications for the treatment of youths with type 1 diabetes, and those at risk of developing type 2 diabetes.
Benefits, Risks of SGLT2 Inhibitors Explored at Session
A symposium on the new drug class, SGLT2 inhibitors, drew plenty of interest from attendees at the American Diabetes Association meeting in San Francisco. SGLT2 inhibitors have gained notice, both for their ability to reduce A1C levels and for their potential to help patients lose weight.